A cost benefit analysis of elimination of kala-azar in Indian subcontinent: An example of Nepal

Journal of Vector Borne Diseases

Volumn 47, Issue 3, 2010, Pages 127-139

  Adhikari, Shiva Raj ^a   Supakankunti, Sirsipen ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Discount rate; Internal rate of return; Intervention; Kala azar; Nepal; Net benefits; Societal benefits; Societal costs

Indexed keywords

ARTICLE; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; CROSS-SECTIONAL STUDY; FEASIBILITY STUDY; HEALTH CARE COST; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NEPAL; PRODUCTIVITY; SENSITIVITY ANALYSIS; VISCERAL LEISHMANIASIS;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DISEASE MANAGEMENT; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; NEPAL;

EID: 77957336292     PISSN: 09729062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ahluwalia IB, Bern C, Costa C, Akter T, Chowdhury R, Ali M, et al. Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. Am J Trop Med Hyg 2003; 69(6): 624-628.
2. Regional strategic framework for elimination of kala-azar from the south-east Asia region (2005-2015): New Delhi: World Health Organization/South East Asia Regional Office. WHO Project No: IND CRD 714. 2005; p. 1-10.
3. Bhattacharya SK, Sur D, Sinha, PK, Karbwang J (Editorial). Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible and operationally achievable. Indian J Med Res 2006; 123: 195-196.
4. Hutubessy RCW, Bendib LM, Evans DB. Critical issues in the economic evaluation of interventions against communicable diseases. Acta Trop 2001; 78: 191-206.
5. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Method for economic evaluation of health care programmes. 2edn. New York: Oxford University Press Inc. 2003; p. 205-225.
6. Arrow KJ, Cropper M L, Eads GC, Hahn RW, Lave LB, Noll RG, et al. Is there a role of cost benefit analysis in environmental, health and safety regulation? Science 1996; 272: 121-122.
7. Mills A. The economic evaluation of malaria control technologies: the case of Nepal. Soc Sci Med 1992; 34: 965-972.
8. Pokharel S, Joshi AB. In detecting visceral leishmaniasis (kala-azar) cases through existing control program cost-effective and early in Nepal? J Nepal Health Res Council 2003; 1(3): 9-16.
9. Baker MC, Mathieu E, Fleming F, Deming M, King JD, Garba A, et al. Mapping, monitoring and surveillance of neglected tropical diseases: towards a policy framework. Lancet 2010; 375: 231-238.
10. Adhikari SR, Maskay NM, Sharma BP. Paying for hospital-based care of kala-azar in Nepal: assessing catastrophe, impoverishment and economic consequences. Health Policy Planning 2009; 24(2): 129-139.
11. Handbook for the economic analysis of the health sector projects. Manila, Philippines: Asian Development Bank 2000; p. 55-62.
12. The annual internal assessment of malaria and kala-azar control activities 2004, 2005 and 2006. Kathmandu, Nepal: Epidemiology and Disease Control Division, Department of Health Services, Ministry of Health, Government of Nepal 2007; p. 29-37.
13. Annual report 2009. Kathmandu, Nepal: Department of Health Services, Ministry of Health and Population, Government of Nepal 2009; p. 145-149.
14. Prasai D. Cost and performance analysis of kala-azar case management. J Nepal Health Res Council 2003; 2: 54-58.
15. Costing of essential health care services package 2001: a report submitted to Ministry of Health, Government of Nepal 2001; p. 1-20.
16. Population monograph of Nepal 2003. Kathmandu, Nepal: Central Bureau of Statistics, Government of Nepal 2003; p. 37-86.
17. Mandal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, et al. Visceral leishmaniasis elimination programme in India, Bangladesh and Nepal: reshaping the case finding/case management strategy. PloS Negl Trop Dis 2009; 3(1): e355.
18. Singh VP, Rajan A, Topno RK, Verma RB, Siddique NA, Ravidas VN, et al. Estimation of under reporting of Visceral leishmaniasis cases in Bihar, India. Am J Trop Med Hyg 2010; 82(1): 9-11.
19. Rijal S, Uranw S, Chappuis F, Picado A, Khanal B, Paudel IS, et al. Epidemiology of Leishmania donovani infection in high-transmission foci in Nepal. Trop Med Int Health 2010; 15 (Suppl 2): 21-28.
20. Rogers ME, Bates PA. Leishmania manipulation of sandfly feeding behaviour results in enhanced transmission. PloS Pathog 2007; 3(6): 818-825.
21. Adhikari SR. Effectiveness of indoor insecticide spray for kala-azar in Nepal. Kathmandu, Nepal: Working Paper Nepal Health Economics Association 2009; p. 1-5.
22. Ranjan A, Sur D, Singh VP, Siddique NA, Manna B, Lal CS, et al. Risk factors for Indian kala-azar. Am J Trop Med Hyg 2005; 73(1): 74-78.
23. Cuddington JT. Modeling the macroeconomic effects of AIDS, with an application to Tanzania. The World Bank Economic Review 1993; 7(2): 173-189.
24. Kim A, Tandon A, Ruiz-tiben E. Cost benefit analysis of the global dracunculiasis eradication campaign policy. Research working paper 1835. Washington DC: The World Bank, African Development Department 1997.
25. Khatiwada YR, Sharma SK. Nepal: country study report 2002. Kathmandu Nepal: Institute for Integrated Development Studies (IIDS) 2002; p. 1-12.
26. Nepal living standard survey 2003-04. Kathmandu, Nepal: Central Bureau of Statistics, Government of Nepal 2004; p. 1-115.
27. Economic survey FY 2007/08. Kathmandu, Nepal: Ministry of Finance, Government of Nepal 2008; p. 1-12.
28. Bassombrio MA, Schofield CJ, Rojas CL, delRey EC. A cost benefits analysis of Chagas disease control in northwestern Argentina. Trans R Soc Trop Med Hyg 1998; 92: 137-143.
29. Briggs A. Handling uncertainty in economic evaluation. BMJ 1999; 319: 120.
30. Rajgopal R, Cox RH, Lambur M and Lewis EC. Cost benefit analysis indicates the positive economic benefit of the expanded food and nutrition education program related to chronic disease prevention. J Nutri Edu Behaviour 2002; 34: 26-37.